Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells-Reference-Cited by-同舟云学术

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells

Published:2017-03-08 Issue:4 Volume:14 Page:1047-1056
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Schardt John S.¹,Oubaid Jinan M.¹,Williams Sonya C.¹,Howard James L.¹,Aloimonos Chloe M.¹,Bookstaver Michelle L.¹,Lamichhane Tek N.¹,Sokic Sonja¹,Liyasova Mariya S.²,O’Neill Maura³,Andresson Thorkell³,Hussain Arif⁴⁵,Lipkowitz Stanley²,Jay Steven M.¹⁵⁶^ORCID

Affiliation:

1. Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States

2. Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States

3. Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States

4. Baltimore VA Medical Center, Baltimore, Maryland 21201, United States

5. Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States

6. Program in Molecular and Cellular Biology, University of Maryland, College Park, Maryland 20742, United States

Funder

Elsa U. Pardee Foundation

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Veterans Affairs

National Heart, Lung, and Blood Institute

NCI-UMD Partnership for Integrative Cancer Research

Publisher